Published in Cardiovascular Week, January 30th, 2006
According to a report from the United States, "Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that modulate gene expression. Therapeutic agents targeting two distinct families of PPARs (alpha and gamma) have been introduced in the United States. The first dual-PPAR agonist, muraglitazar, was reviewed by a U.S. Food and Drug Administration (FDA) advisory committee on September 9, 2005, resulting in a vote of 8:1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week